Aberdeen Group plc Acquires 43,990 Shares of DexCom, Inc. $DXCM

Aberdeen Group plc increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 9.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 530,363 shares of the medical device company’s stock after buying an additional 43,990 shares during the period. Aberdeen Group plc owned about 0.14% of DexCom worth $35,200,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom during the second quarter worth $26,000. SJS Investment Consulting Inc. grew its position in shares of DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. acquired a new stake in shares of DexCom in the third quarter valued at about $29,000. CVA Family Office LLC raised its position in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the last quarter. Finally, ORG Partners LLC raised its position in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DXCM has been the topic of several analyst reports. Canaccord Genuity Group set a $95.00 target price on DexCom and gave the company a “buy” rating in a report on Friday, February 13th. Truist Financial restated a “buy” rating and set a $80.00 price target (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Morgan Stanley restated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective on the stock in a research note on Tuesday, March 24th. Finally, Barclays reiterated an “underweight” rating and set a $72.00 price objective (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $86.50.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00. Following the transaction, the executive vice president directly owned 112,904 shares of the company’s stock, valued at approximately $7,321,824.40. This represents a 1.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.32% of the company’s stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $62.22 on Friday. The company has a fifty day moving average of $69.11 and a 200-day moving average of $67.14. The firm has a market capitalization of $23.95 billion, a P/E ratio of 29.63, a P/E/G ratio of 1.21 and a beta of 1.55. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The company had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the previous year, the company earned $0.45 EPS. DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.